Research Guide: Tirzepatide

The Dual Agonist

Tirzepatide is unique because it acts on two receptors, not just one:

1. GLP-1 (Glucagon-Like Peptide-1): Same target as Semaglutide (satiety, insulin control).
2. GIP (Glucose-Dependent Insulinotropic Polypeptide): A hormone that also stimulates insulin but may improve fat metabolism and reduce nausea compared to pure GLP-1s.

The "Twincretin" effect creates a synergy that has shown superior weight loss results in clinical trials compared to GLP-1 mono-agonists.

Pharmacokinetics

Half-Life: Approximately 5 days (120 hours).

Technically shorter than Semaglutide, but still effective with once-weekly dosing. The peak concentration hits about 8-72 hours after administration.

Typical Research Titration

Tirzepatide has a higher milligram-for-milligram dosing scale than Semaglutide:

• Month 1: 2.5mg / week (Loading dose)
• Month 2: 5.0mg / week
• Month 3: 7.5mg / week
• Month 4: 10.0mg / week
• Month 5: 12.5mg / week
• Month 6+: 15.0mg / week (Max dose)